|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
fyi - New - Note the "eHealthMe" reports, posted @ right, bottom
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AERS reported to the FDA during 01/05 - 12/06 :
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(1):
Lupron/leuprolide EXPOSURE BEFORE PREGNANCY, TRANS- PLACENTAL EXPOSURE, and CONGENITAL ANOMALIES:
Note: the below FDA AERS Reports represent most of those reports found for the time period of January 2005 - December 2006
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cerebral Palsy, Congenital Anomaly, Fetal Disorder After Exposure to Lupron 3.75 mg (10-26-05)
Trisomy 21 After Exposure to Leuprolide 0.2 ml Before Pregnancy (01-05-06)
Neonatal Anemia, Jaundice, Respiratory Disorder After Exposure to Enantone (leuprolide) 3.75 mg (03-29-06)
Death of Newborn Male Infant From Multi-Organ Failure, Congenital Heart Disease, Skull Malformation, Trisomy 13 After Transplacental Exposure to Lupron Depot 3.75 mg (08-31-06)
Congenital Foot Malformation After Maternal Exposure to 3 Months of Enantone-Gyn (leuprolide) 3.75 mg (12-04-06)
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(2):
OVARIAN HYPERSTIMULATION
SYNDROME (OHSS)
Note: the below FDA AERS Reports represent All reported OHSS for the time period January 2005 - December 2006.
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
OHSS Develops In a 30 Year Old Female After Leuprolide (04-18-05)
OHSS Develops In a 33 Year Old Female After Lupron (05-06-05)
OHSS Develops In a 32 Year Old Female After 11 Days of Leuprolide (01-12-06)
OHSS Develops In a 32 Year Old Female After 11 Days of Leuprolide 0.5/0.25 mgs (02-20-06)
OHSS Develops In a 32 Year Old Female After 11 Days of Leuprolide (03-22-06)
OHSS Develops In a 39 Year Old Female After Lupron (05-04-06)
OHSS Develops In a 29 Year Old Female After Leuplin 1.88 mg (08-09-06)
OHSS Develops In a 38 Year Old Female After 1 Injection of Leuprorelin (12-21-06)
OHSS Develops In a 38 Year Old Female After 1 Day of Enantone 1.87 mg (12-28-06)
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(3):
LIFE-THREATENING ILLNESSES HOSPITALIZATIONS, DISABILITIES, OTHER, post- Lupron/leuprolide
Note: the below FDA AERS Reports represent selected reports, and are not all inclusive, and pertain only to the time period of January 2005 - December 2006 (plus a few entries for 2004 have been posted).
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
44 Year Old Female With Cerebral Hemorrhage, Aphasia, Hemiplegia After Leuplin 3.75 mg (01-07-04)
52 Year Old Female With Amnesia, Confusional State, Depression, Vomiting After Lupron Depot 3.75 mg (01-09-04)
31 Year Old Female With Amnesia, Convulsions, Fibromyalgia, Transient Ischemic Attack, Caeserean Section, Muscular Atrophy, Heart Rate Increase, Angina Pectoris, and Bone Pain, (among others) After One Injection of Lupron Depot 3.75 mg (01-16-04)
49 Year Old Female With Impaired Work Ability, Musculoskeletal Stiffness, Sed Rate Increase After One Injection of Lupron (01-20-04)
Female With Pancytopenia After Six Injections of Leuplin 1.88 mg (02-05-04)
---------------
28 Year Old Female With Acute Lymphocytic Leukemia After Leuplin 1.88 mg (01-18-05)
Female With Breast Cancer After Lupron (01-18-05)
26 Year Old Female With Pituitary Tumor, Arthralgia, Depression, Memory Impairment, Migraine, Muscle Spasms After Lupron Depot (01-25-05)
70 Year Old Male With Pulmonary Embolism 19 Days After Eligard (leuprolide) (01-26-05)
72 Year Old Male, In Study, With Aortic Valve Disease, Cerebrovascular Accident, Myocardial Ischemia, Pulmonary Hypertension After Intravenous Lucrin (leuprolide) (01-27-05)
75 Year Male, In Study, With Retinal Vein Thrombosis After Oral Leuprolide 3.75 mg (03-09-05)
11 Year Old Female With Hypothyroidism, Malignant Melanoma After "Intracardiac" Leuprorelin 1.88 mg (03-10-05)
34 Year Old Female With Gastrointestinal Erosion, Necrosis, Recatal Hemorrhage After Lupron 3.75 mg (03-16-05)
29 Year Old Female With Benign Intracranial Hypertension After Lupron Depot 3.75 mg (03-29-05)
41 Year Old Female With Hemorrhagic Stroke After Lupron 3.75 mg (03-30-05)
71 Year Old Male With Hepatic Failure, Hepatic Neoplasm, Gastric Ulcer, Perhipheral Edema After 6 Months of Leuplin 3.75 & 3 Months of Leuplin 11.25 mg (04-14-05)
35 Year Old Female With Pancytopenia After 2 Months of Leuplin 3.75 mg (04-27-05)
34 Year Old Female With Osteoporosis After Lupron 3.75 & 11.25 mg (05-05-05)
44 Year Old Female With Hemiparesis, Dizziness, Facial Palsy After Lupron 3.75 mg (05-11-05)
15 Year Old Male With Insulin Dependent Diabetes Mellitus After Lupron (05-12-05)
92 Year Old Male With General Health Deterioration, Disseminated Intravascular Coagulation, Rhabdomyolysis After Leuplin 3.75 mg (05-19-05)
76 Year Old Male With Dementia, Cerebrovascular Disorder, Vascular Encephalopathy After Trenantone (leuprolide) 11.25 mg (05-24-05)
55 Year Old Female With Transient Ischemic Attack, Cerebrosclerosis, Cerebrovascular Disorder After 1 Month of Leuplin 1.55 mg (05-26-05)
81 Year Old Male With Bone Marrow Failure After Leuplin 11.25 mg (06-01-05)
72 Year Old Male, In Study, With Nervous System Disorder, Cardiovascular Disorder After 15 Months of Lucrin (leuprolide) 22.5 mg (06-02-05)
Male With Myocardial Infarction After Eligard (leuprolide) (06-10-05)
45 Year Old Female With Disability From Amnesia, Bone Pain, Fatigue, Depression, Muscular Weakness After Lupron 11.25 & 3.75 mg (06-16-05)
73 Year Old Male With Aortic Arteriosclerosis, Intervertebral Disc Degeneration, Mitral Valve Stenosis, Ventricular Hypertrophy After 85 Days of Lucrin (leuprolide) 22.5 mg (06-20-05)
26 Year Old Female With Cardiac Arrest, Convulsion, Loss of Consciousness After Lupron Depot-3 11.25 mg (06-24-05)
27 Year Old Female With Disability From Decreased Mobility, Pain After Lupron 3.75 mg (07-20-05)
28 Year Old Female With Colon Cancer Stage IV After Leuprolide in IVF (08-03-05)
35 Year Old Female With Bone Marrow Failure, Pancytopenia After 2 Months of Lupron 3.75 mg (10-03-05)
45 Year Old Female With Unilateral Blindness After 3 Months of Lupron (10-11-05)
23 Year Old Female With Benign Pituitary Tumor, Hemiplegia, Facial Paralysis After 1 Dose of Lupron Depot-3 11.25 mg (01-10-06)
23 Year Old Female With Cervical Myelopathy, Upper Motor Neuron Lesion After Lupron Depot-3 11.25 mg (02-08-06)
Female With Brain Edema After Days of Enantone (leuprolide) 11.25 mg (03-10-06)
39 Year Old Female With Subarachnoid Hemorrhage After Lupron 3.75 mg (03-10-06)
70 Year Old Male With Acute Myeloid Leukemia, Bone Marrow Failure After 9 Months of Leuplin (leuprolide) 11.25 mg (03-29-06)
45 Year Old Female With Ovarian Adenoma After Leuprolide 11.25 mg (04-04-06)
36 Year Old Female With Suicide Ideation, Depression After 1 Injection of Lupron Depot (04-12-06)
47 Year Old Female With Cerebrovascular Accident, Multiple Sclerosis, Cognitive Disorder After 2 Injections of Lupron Depot 3.75 mg (04-17-06)
35 Year Old Female With Hemorrhagic Ovarian Cyst, Ruptured Ovarian Cyst After 2 Months of Lupron 1.88 mg (07-07-06)
Female With Convulsion After Leuprorelin (07-17-06)
43 Year Old Female With Abdominal Distension, Ascities After 2 Months of Leuplin 3.75 mg (07-19-06)
71 Year Old Male With Renal Failure After 6 Months of Leuprolide 22.5 mg (07-24-06)
85 Year Old Male With Rectal Cancer After Leuplin (08-04-06)
35 Year Old Female With Hemorrhagic Ovarian Cyst, Ovarian Cyst Rupture (08-07-06)
61 Year Old Male With IIIrd Nerve Paralysis, Pituitary Hemorrhage After Eligard (leuprolide) (08-09-06)
24 Year Old Female With Amnesia, Osteopenia After Lupron Depot 3.75 & 11.25 mg (08-23-06)
16 Year Old Female With Amnesia, Thyroid Disorder After Lupron Depot 11.75 mg (08-28-06)
50 Year Old Female With Disseminated Intravascular Coagulation, Hemorrhage After Leuplin 1.88 mg (09-21-06)
61 Year Old Male With Throat Cancer After Lupron Depot-4 30 mg (09-26-06)
38 Year Old Female With Disseminated Intravascular Coagulation, Hemorrhage After Leuplin 1.88 mg (09-28-06)
10 Year Old Female With Epiphysioloysis After Lupron Depot-Ped 15 mg (10-04-06)
Female With Embolism After Lupron Depot 3.75 mg (10-17-06)
28 Year Old Female With Systemic Lupus Erythematosus, Loss of Consciousness, Tremor, Blurred Vision After Lupron Depot-3 Month 11.25 mg (10-17-06)
40 Year Old Female With Empty Sella Syndrome, Hypothyroidism, Pituitary Hemorrhage, Secondary Hypogonadism After Lupron Injection (10-24-06)
66 Year Old Male With Cerebral Hemorrhage, Arthralgia, Depression After Lupron 7.5 mg (10-31-06)
29 Year Old Female With Hyperthyroidism, OHSS, Intestinal Obstruction After 6 Months of Leuplin 1.88 mg (11-02-06)
38 Year Old Female With Uterine Cancer After 2 Months of Leuplin 1.88 mg (11-08-06)
47 Year Old Female With Ovarian Cancer After Leuplin Depot (11-14-06)
46 Year Old Female With Osteoporosis, Spinal Column Stenosis, Disc Degeneration, Fracture After Lupron Depot 3.75 mg (11-21-06)
34 Year Old Female With Paralysis, Mental Disorder After Lupron (12-04-06)
61 Year Old Male With Pituitary Hemorrhage After Leuprolide (12-08-06)
32 Year Old Female Bedridden With Cardiovascular Disorder, Cerebellar Ataxia, CFS, Hypopituitarism, Systemic Lupus Erythematosus, etc. After 4 Months of Enantone-Gyn (leuprolide) 3.75 mg (12-08-06)
44 Year Old Female With Cyanosis After Leuplin (leuprolide) 3.75 mg (12-20-06)
59 Year Old Male With Scrotal Cancer After Lupron Depot-4 Month 30 mg (12/28/06)
|
AERS = FDA AERS (Adverse Event Reporting System) FOI Reports
This page will provide information on the adverse events reported to the FDA for lupron/leuprolide in men, women, children, fetuses, and babies for the time period of January 2005 through December 2006 only (23 months worth of AERS). These AERS reports, at left, obtained under FOI (Freedom of Information) Act, are divided as follows:
(1) Most reports found for the period of January 2005 through December 2006 related to 'Drug Exposure Before Pregnancy', 'Transplacental Exposure' and 'Congenital Anomalies', including death; (for a listing of fetal deaths for period of 11/97 - 12/04, see 'Deaths' page, at bottom)
(2) All reports found for the period of January 2005 through December 2006 related to Ovarian Hyperstimulation Syndrome (OHSS); and
(3) Selective reports (and *not* a comprehensive list) of 'Life-Threatening' and 'Disabling' illnesses, 'Hospitalizations' and 'Other' adverse events for the period of January 2005 through December 2006.
The AERS FOI Reports reproduced at left contain all information as found in the FDA AERS FOI Reports. Additional information beyond that listed in the AERS FOI Reports can be obtained from the FDA by requesting individual ISR# (Individual Safety Numbers) reports.
It should be noted that only 1% to 10% of all adverse events are reported to the FDA, therefore 90% to 99% of adverse events remain unreported to the FDA AERS.
The FDA, in it's AERS FOI Reports, defines "Preferred Term" as "The reported reaction, in medical terminology [coded by MedDRA], describing the event." "Suspect Drug" is defined as "The drug that the initial reporter deemed most likely to be associated with the reactions." And "Concomitant Drug" is defined as "A list of drugs taken at the same time as the suspect medication, but not suspected of causing the adverse event."
*******************************************************************
Definitions for medical terms can be found at the following links:
www.medterms.com
http://www.nlm.nih.gov/medlineplus/mplusdictionary.html
*******************************************************************
The following are links to reports of adverse events to lupron/leuprolide found on the eHealthMe website: (recall that approximately only 1% to 10% of all adverse events ever wind up being "reported") -
See Top Ten Overall Lupron Side effects
20 Reports of Rash
87 Reports of Pulmonary Embolism
10 Reports of Malignant Hepatic Neoplasm
15 Reports of Malignant Neoplasm
27 Reports of Jaundice
45 Reports of Metastases to Liver
15 Reports of Abscess
32 Reports of Erythema
25 Reports of Cholelithiasis
33 Reports of Diabetes
31 Reports of Constipation
84 Reports of Pyrexia
18 Reports of Cardiac Failure Congestive
13 Reports of Pain in Extremety
13 Reports of Pollakiuria
20 Reports of Myalgia
11 Reports of Bedridden
290 Reports of Fatigue
270 Reports of Asthenia
260 Reports of Nausea
259 Reports of Arthralgia
235 Reports of Hot Flush
224 Reports of Pain
194 Reports of Pyrexia
191 Reports of Osteonecrosis
182 Reports of Headache
168 Reports of Dyspnea
3 Reports of Hemolysis
-----------------------------------------------
This page is under construction.
|
|